CBI-1214 / Cartography Biosci - LARVOL DELTA

Cartography Biosciences Doses First Patient in Phase 1 Trial of CBI-1214, a Highly Specific T-Cell Engager for the Treatment of Colorectal Cancer (Businesswire) - "The Phase 1, first-in-human, open-label study will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CBI-1214, a novel T-cell engager, in adult participants with advanced or metastatic microsatellite stable (MSS) or microsatellite instability-low (MSI-L) colorectal cancer."

First-in-human • Trial status • Colorectal Cancer • Microsatellite Instability

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Cartography Biosciences

First-in-human • New P1 trial • Colon Cancer • Colorectal Cancer • Microsatellite Instability • Oncology • Solid Tumor • MSI

Cartography Receives FDA Investigational New Drug (IND) Approval and Fast Track Designation for Lead Program CBI-1214 for Colorectal Cancer (PharmiWeb) - "Cartography anticipates initiating its Phase I clinical trial in the first quarter of 2026."

Fast track • IND • New P1 trial • Colorectal Cancer